Five things for pharma marketers to know: Friday, September 11, 2015

Proteus Digital Health and Otsuka Pharmaceutical said the FDA had accepted an application combining Otsuka's antipsychotic Abilify with a Proteus ingestible sensor. The sensor would track medication adherence as well as a patient's physiologic response and could be used to notify providers about medication lapses, which are not unusual for patients with schizophrenia, the companies said.

Johnson & Johnson moved its US media-buying business back to J3, which is a J&J-dedicated unit of Interpublic Group's UM, Advertising Age reported. The healthcare giant had moved its US buying business to Omnicom Group's OMD last year.

An FDA advisory committee recommended against approving Purdue Pharma's long-acting abuse-deterrent opioid painkiller, Avridi, Reuters reported. The committee voted 23-1 against approval and also expressed similar concerns over Collegium's experimental opioid pain drug, which is set to be reviewed by the FDA committee on Friday.

Amgen submitted an application to the FDA for a new dosing schedule for Repatha, its recently approved PCKS9 inhibitor. The drugmaker is seeking approval to market the cholesterol-lowering drug as a single monthly injection. It is currently approved to be injected every two weeks or as three injections once a month.  

Acetelion is in talks to acquire ZS Pharma, according to Reuters. Bloomberg Business had previously reported that Actelion sought to acquire ZS Pharma in a deal valued at $2.5 billion.


Correction: An earlier version of this story incorrectly described the number of injections in a Repatha regimen. We apologize for the error.